4-morpholinoquinolin-2-amine | 1029128-01-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-morpholinoquinolin-2-amine
• 英文别名: 4-Morpholin-4-ylquinolin-2-amine
• CAS: 1029128-01-5
• 化学式: C₁₃H₁₅N₃O
• 分子量: 229.282
• InChiKey: LSGAWULNENTZPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  51.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,2-二甲基丁酰氯 、 4-morpholinoquinolin-2-amine 在 三乙胺 、 盐酸 作用下， 以 二氯甲烷 、 乙醚 为溶剂， 反应 5.0h， 以29%的产率得到2,2-dimethyl-N-(4-morpholinoquinolin-2-yl)butanamide dihydrochloride
  参考文献：
  名称：

  WO2008/63625

  摘要：

  公开号：
• 作为产物：
  描述：

  4-氯喹啉-N-氧化物 在 4-甲苯磺酸酐 、 叔丁胺 作用下， 以 N-甲基吡咯烷酮 、 二氯甲烷 为溶剂， 反应 3.75h， 生成 4-morpholinoquinolin-2-amine
  参考文献：
  名称：

  Developing Inhibitors of the p47phox–p22phox Protein–Protein Interaction by Fragment-Based Drug Discovery

  摘要：

  Nicotinamide adenine dinucleotide phosphate oxidase isoform 2 is an enzyme complex, which generates reactive oxygen species and contributes to oxidative stress. The p47phox-p22phox interaction is critical for the activation of the catalytical NOX2 domain, and p47phox is a potential target for therapeutic intervention. By screening 2500 fragments using fluorescence polarization and a thermal shift assay and validation by surface plasmon resonance, we found eight hits toward the tandem SH3 domain of p47phox (p47phox(SH3A-B)) with K-D values of 400-600 mu M. Structural studies revealed that fragments 1 and 2 bound two separate binding sites in the elongated conformation of p47phox(SH3A-B) and these competed with p22phox for binding to p47phox(SH3A-B). Chemical optimization led to a dimeric compound with the ability to potently inhibit the p47phox(SH3A-B)-p22phox interaction (K-i of 20 mu M). Thereby, we reveal a new way of targeting p47phox and present the first report of drug-like molecules with the ability to bind p47phox and inhibit its interaction with p22phox.

  DOI：

  10.1021/acs.jmedchem.9b01492

文献信息

• [EN] PYRIDINE COMPOUNDS AND METHODS OF THEIR USE<br/>[FR] COMPOSÉS PYRIDINIQUES ET PROCÉDÉS RELATIFS À LEUR UTILISATION
  申请人：ADOLOR CORP

  公开号：WO2008063625A2

  公开（公告）日：2008-05-29

  [EN] Novel pyridine compounds, pharmaceutical compositions containing the pyridine compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the pyridine compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, inflammation, auto-immune diseases, ischemic conditions, immune-related disorders, hypertension, neurological disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, for inhibiting mechanical hyperalgesia associated with nerve injury, and as an appetite stimulant.
  [FR] La présente invention concerne de nouveaux composés pyridiniques, des compositions pharmaceutiques contenant les composés pyridiniques, et des procédés relatifs à leur utilisation pharmaceutique. Dans certains modes de réalisation, les composés pyridiniques sont des agonistes et/ou des ligands des récepteurs cannabinoïdes et peuvent servir, entre autres, à traiter et/ou prévenir une douleur, des troubles gastro-intestinaux, une inflammation, des maladies auto-immunes, des états ischémiques, des troubles immunitaires, une hypertension, des troubles neurologiques, et des maladies neurodégénératives. Il est possible ainsi d'assurer une protection cardiaque contre les effets ischémiques et de reperfusion, d'induire une apoptose des cellules cancéreuses, d'inhiber l'hyperalgésie mécanique associée aux lésions nerveuses, et de stimuler l'appétit.
• WO2008/63625
  申请人：——

  公开号：——

  公开（公告）日：——
• Developing Inhibitors of the p47phox–p22phox Protein–Protein Interaction by Fragment-Based Drug Discovery
  作者：Sara Marie Øie Solbak、Jie Zang、Dilip Narayanan、Lars Jakobsen Høj、Saskia Bucciarelli、Charlotte Softley、Sebastian Meier、Annette Eva Langkilde、Charlotte Held Gotfredsen、Michael Sattler、Anders Bach

  DOI：10.1021/acs.jmedchem.9b01492

  日期：2020.2.13

  Nicotinamide adenine dinucleotide phosphate oxidase isoform 2 is an enzyme complex, which generates reactive oxygen species and contributes to oxidative stress. The p47phox-p22phox interaction is critical for the activation of the catalytical NOX2 domain, and p47phox is a potential target for therapeutic intervention. By screening 2500 fragments using fluorescence polarization and a thermal shift assay and validation by surface plasmon resonance, we found eight hits toward the tandem SH3 domain of p47phox (p47phox(SH3A-B)) with K-D values of 400-600 mu M. Structural studies revealed that fragments 1 and 2 bound two separate binding sites in the elongated conformation of p47phox(SH3A-B) and these competed with p22phox for binding to p47phox(SH3A-B). Chemical optimization led to a dimeric compound with the ability to potently inhibit the p47phox(SH3A-B)-p22phox interaction (K-i of 20 mu M). Thereby, we reveal a new way of targeting p47phox and present the first report of drug-like molecules with the ability to bind p47phox and inhibit its interaction with p22phox.